Feb. 23, 2026
Reimbursement policies, formerly known as clinical payment and coding policies, describe payment rules and methodologies for Current Procedural Terminology (CPT®) codes, Healthcare Common Procedure Coding System and ICD-10 coding for claims submitted as covered services. This information is a resource for our payment policies. It’s not intended to address all reimbursement-related issues. We regularly add and modify coding and compensation policy positions as part of our ongoing policy review process.
The following policies were updated:
- CPCP041 Sepsis Policy, effective April 30, 2026
- CPCPLAB067 Testing of Homocysteine Metabolism-Related Conditions effective May 1, 2026
- CPCPLAB003 Vitamin D, effective May 1, 2026
- CPCPLAB008 Diagnostic Testing of Iron, effective May 1, 2026
- CPCPLAB009 Testosterone, effective May 1, 2026
- CPCPLAB010 Vitamin B12 and Methylmalonic Acid Testing, effective May 1, 2026
- CPCPLAB023 Diagnosis of Idiopathic Environmental Intolerance, effective May 1, 2026
- CPCPLAB028 Immune Cell Function Assay, effective May 1, 2026
- CPCPLAB038 Urinary Tumor Markers for Bladder Cancer, effective May 1, 2026
- CPCPLAB064 Nerve Fiber Density Testing, effective May 1, 2026
- CPCPLAB069 Immunohistochemistry, effective May 1, 2026
CPT copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the AMA.
Reimbursement policies are based on using healthcare professionals and industry standard guidelines. The reimbursement guidelines are not intended to provide billing or coding advice but to serve as a reference for facilities and providers.